Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Good safety and pharmacokinetic profile of XP-19986 in healthy volunteers

July 20, 2005

SPA agreement for phase III study of renzapride for c-IBS

July 19, 2005

Migenix and Schering-Plough sign agreement for MX-3253

July 18, 2005

Gentium's CMC submission adequate for phase III trial of defibrotide

July 18, 2005

New agents for gastrointestinal disorders described in recent patent literature

July 15, 2005

Hepatitis B virus responses maintained with long-term adefovir therapy

July 14, 2005

Enrollment completed in phase III trial of Infergen for HCV

July 13, 2005

Peginterferon alfa-2a reported more effective than lamivudine in hepatitis B

July 13, 2005

Napo and Glenmark collaborate on crofelemer development

July 12, 2005

NV-52 enters phase I for inflammatory bowel disease

July 12, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...